Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models

Non-muscle-invasive bladder cancer (NMIBC) can progress to muscle-invasive disease, with transurethral resection followed by Bacillus Calmette-Guérin (BCG) immunotherapy reducing this risk. Effective immunotherapies for BCG-resistant NMIBC are lacking. This study directly compares the efficacy of th...

Full description

Saved in:
Bibliographic Details
Main Authors: Lauren Daniel, Kowry S. Ndiaye, Hugo Giguère, Léa J. Custeau, Jacob L. Léger, Guillaume St-Cyr, Nadia Ekindi Ndongo, Patrick O. Richard, Lee-Hwa Tai
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Therapy: Oncology
Subjects:
BCG therapy
BCG failure
immunotherapy
oncolytic virus
tumor microenvironment
nonmuscle invasive bladder cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000852
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items